NCI-2024-00168

A Phase IIIb, Randomized, Multicenter, Open-label Study toassess the Efficacy of Durvalumab plus Tremelimumab versusPembrolizumab in Combination with Platinum-BasedChemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

The TRITON study is a Phase IIIb research study comparing two treatment approaches for metastatic non-small cell lung cancer patients with non-squamous histology and specific genetic mutations (STK11, KEAP1, or KRAS). It aims to determine whether durvalumab plus tremelimumab (immunotherapy drugs) is more effective than pembrolizumab plus platinum-based chemotherapy as first-line treatment. The trial is randomized, multicenter, and open-label, focusing on evaluating treatment efficacy and potentially improving outcomes for these patients. Durvalumab plus Tremelimumab are immunotherapy drugs that work by helping the immune system fight cancer cells. Durvalumab targets a protein called PD-L1, while tremelimumab enhances the immune response against cancer cells. Pembrolizumab is another immunotherapy drug that also targets PD-L1. It is combined with standard platinum-based chemotherapy, which is a common treatment approach for NSCLC. The goal of the TRITON trial is to determine which treatment regimen provides better outcomes in terms of effectiveness and potentially improving survival for patients with this specific type of lung cancer and genetic profile.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06008093

Clinical Trial Site: Columbia

To see all available clinical trials click here.